Eli Lilly & Co. vs Roivant Sciences Ltd.
LLY vs ROIV — side-by-side comparison from reported financials. LLY leads 7, ROIV leads 3 of 10 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Roivant Sciences Ltd.
ROIV · Healthcare
$35.44+3.60%Strong
| Metric | LLY | ROIV |
|---|---|---|
| Price | $1 177.20 | $35.44 |
| Market cap | $1.05T | $25.6B |
| Revenue (TTM) | $79.7B | $16.9M |
| Revenue growth | +31.7% | -48.7% |
| Net margin | 33.5% | -7594.2% |
| Free cash flow | $18.2B | -$1.89B |
| Net cash (debt) | ($35.2B) | $3.73B |
| 1-year price return | +37.6% | +119.9% |
| P/E | 41.6 | — |
| P/E vs own history (cheap-side %) | 88% | 73% |
| Dividend yield | 0.52% | — |
| Return on equity | 93% | -6% |
| Altman Z-score | 7.10 | 40.50 |
| CV checks passed | 11 of 11 | 5 of 11 |
| Employees | 50,000 | 721 |
Full résumé-style profiles: LLY CV · ROIV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.